

**Category**

Best Incubator, Accelerator, Equity

**Program/Fund Name**

Johnson & Johnson Innovation – JLABS

**Corporate Name**

Johnson & Johnson Innovation

**Date Of Creation**

2012-01-01

**Indications (if applicable)**

N/A

**Therapeutic Categories (if applicable)**

N/A

**History of the development of the fund / Incubators**

NOT FOR PUBLICATION

Over a decade ago, The Johnson & Johnson Family of Companies (Johnson & Johnson) began building a new model of innovation for health in the birthplace of biotech, San Francisco. The company vowed to make it just as attractive to innovate in healthcare as it was in tech, with the aim to empower a global network to fight for our health.

In 2012, the first Johnson & Johnson Innovation – JLABS (JLABS) site opened its doors with four startups. Since then, JLABS has grown to be the most diverse global incubator network of 900+ (300+ in residence) early-stage life science innovators across 12 sites in North America, Europe and Asia; with BLUE KNIGHT™—our collaboration with BARDA that aims to stimulate the innovation and incubation of science and technologies that has as a goal to help improve health security and response by supporting companies focused on public health threats and emerging infectious diseases—available across all sites; and more than 80 QuickFire Challenge opportunities launched to date—aiming to identify, support and accelerate the most promising ideas in healthcare. In 2022, we celebrate a decade of incubating the dreams of founders and entrepreneurs at JLABS, together with life science innovators and the communities we're here to serve.

JLABS makes diversity a priority and believes in order to understand the people we're trying to serve, all types of people across genders, races, religions, geographies and socioeconomic status must be represented in our network. Today, JLABS companies are 33% women-led and 31% minority-led—and JLABS aims to bring that diverse insight to its priorities and plan for filling key gaps.

Johnson & Johnson Innovation aims to connect startups with a partner at every stage—starting with early-stage innovation at JLABS. JLABS supports through incubation, growth and optimization of startups' research and development through industry connections, entrepreneurial programs and access to capital-efficient resources and lab space.

**Focus**

Startup incubation

**How do you address your portfolio needs**

N/A

**Impact / metrics to measure success**

NOT FOR PUBLICATION

According to JLABS Navigator (<https://www.jnjinnovation.com/JLABSNavigator>), our portfolio intelligence tool and customized solution to search and find companies in areas of interest, our network includes:

- 938 JLABS companies
- 49 publicly traded companies
- 42 companies acquired
- \$88.4 billion in financing and strategic relationships (secured and contingent)
- 43% serial entrepreneurs
- 57% first-time entrepreneurs
- 33% female-led companies
- 31% minority-led companies
- 200+ companies with at least one deal with a company from Johnson & Johnson

**Why your model is innovative, and/or how it will improve the human condition?**

JLABS offers a “no-strings-attached” model:

- JLABS takes no IP or rights in JLABS companies
- Get started without significant funding
- Know-how & connections to be party-ready
- Get to go/no-go decisions sooner
- Better bottom line for investors

Through the Johnson & Johnson Innovation network, JLABS offers startups an entry point to a global network, and Johnson & Johnson:

- JLABS aims to make it easy for collaborators to connect with JLABS companies, all over the globe. Johnson & Johnson Innovation operates in every innovation region of the world, with hubs in Boston, London, South San Francisco and Shanghai.
- JLABS provides access to its investor community, including JJDC, Inc. (our venture capital arm) which invests across sectors and at all stages.
- JLABS helps ensure partnerships are considered for future opportunities, including with Janssen Business Development (JBD), spanning the pharmaceuticals, MedTech and consumer

health sectors.

### **Please provide appropriate references (Examples / Case Study)**

#### **JPALS**

Expertise and connections to support startup growth powered by experts across Johnson & Johnson.

#### **JLABS Navigator**

Johnson & Johnson Innovation's exclusive interactive guide showcasing current JLABS residents and alumni.

#### **Programming and networking**

Workshops, networking events, access to experts across Johnson & Johnson webinars, and educational resources.

#### **Investor Hub**

Our Investor Hub brings local, regional and global investors and portfolio companies together for investment consideration, expertise and relationship building. Investor Hub's goal is to make connections between healthcare investors around the globe. We began in 2017 with one external investment firm and now we have more than 100 groups engaged worldwide.

- More than 200 investor events facilitated by JLABS
- More than 1,900 investor meetings facilitated by JLABS

#### **Resource Hub**

Support for small companies comes in many different forms. At JLABS we work with external sponsors to provide a strong community of resources for our residents. This network is strengthened by our internal procurement team who is leveraging the network of external providers of Johnson & Johnson, to help deliver benefits that aim to reduce costs, increase access and improve knowledge of JLABS residents.

#### **BLUE KNIGHT™**

Blue Knight is a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies that may improve health security and response by supporting companies focused on public health threats and emerging infectious diseases. We announced our collaboration in April 2019. In the time since, the portfolio has grown to 37 companies and counting.

#### **QuickFire Challenges**

Johnson & Johnson Innovation's QuickFire Challenge opportunities aim to identify, support and accelerate the most promising ideas in healthcare, and continue to lead response across a variety of diversity and healthcare disparity-driven initiatives.